Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02333188CT.gov Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | — | Completed | — | — | — |
NCT01206465CT.gov Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors | — | Completed | — | — | — |
NCT00610948CT.gov Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment | — | Completed | — | — | — |
NCT00138177CT.gov Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors | — | Completed | — | — | — |
NCT00080990CT.gov Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00042861CT.gov UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors | — | Completed | — | — | — |
NCT00042874CT.gov Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00021073CT.gov Combination Chemotherapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00004059CT.gov Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors | — | Completed | — | — | — |
NCT00003956CT.gov Combination Chemotherapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT00004875CT.gov Heparin or Enoxaparin in Patients With Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer Of Unknown Primary Site
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluorouracilum (this asset) | Alliance for Clinical Trials in Oncology | P2 | BB · 71 |
| Nepenthe | M.D. Anderson Cancer Center | P4 | BBB |
| Amifostine | M.D. Anderson Cancer Center | P4 | BBB |
| Etoposide | University of California, Davis | P2/3 | BBB |
| Dexasone | Alliance for Clinical Trials in Oncology | P3 | BBB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P3 | BBB |
| Melphalan | City of Hope Medical Center | P2/3 | BBB |
| Nivestim | National Institutes of Health Clinical Center (CC) | P3 | BBB |
| Sargramostim | Barbara Ann Karmanos Cancer Institute | P2 | BBB |
+42 more in the Cancer Of Unknown Primary Site cohort
Other indications for Fluorouracilum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 77 |
| Rectal Cancer | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluorouracilum in Cancer Of Unknown Primary Site. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluorouracilum-cancer-of-unknown-primary-site
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →